Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis

View original at nasdaq.com
Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis Key Points Ford Credit is one of the automaker's most profitable units…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ford Motor Company was not among the 10 best stocks for investors to buy now

    60% confidence
  • Industry experts are expecting the resale value of off-lease EVs will check in around $10,000 less than automaker finance entities projected, and could range anywhere from $5,000 to $20,000 less

    60% confidence
  • Roughly 228,000 Tesla EVs were leased last year, nearly 102,000 EV leases for General Motors, and a little over 52,000 EV leases for Ford

    60% confidence
  • Using the $10,000 figure, that would be an industrywide loss of about $8 billion for expected models coming off lease in 2028

    60% confidence
  • Stock Advisor's total average return is 914% compared to 184% for the S&P 500

    60% confidence
  • Off-lease EV volume will peak in 2028 with nearly 800,000 EVs flooding the market

    60% confidence
  • Ford Credit typically generates only about 5% of revenue any given year but provides 15% to 20%, sometimes more, of the company's profits

    60% confidence
  • EVs expected to make up 15% of off-lease used vehicles by the end of 2026, compared to only 7.7% during the first quarter

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis — Source | Via News | ViaNews Market